UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000048362
Receipt number R000055119
Scientific Title Research for analyzing the relationship between glucose levels and the pulse-wave augmentation index (Aindex ) , measured by a gyro sensor.
Date of disclosure of the study information 2022/07/20
Last modified on 2024/03/13 15:25:10

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Research for analyzing the relationship between glucose levels and the
pulse-wave augmentation index (Aindex ) , measured by a gyro sensor.

Acronym

Research for analyzing the relationship between glucose levels and the
pulse-wave augmentation index (Aindex ) , measured by a gyro sensor.

Scientific Title

Research for analyzing the relationship between glucose levels and the
pulse-wave augmentation index (Aindex ) , measured by a gyro sensor.

Scientific Title:Acronym

Research for analyzing the relationship between glucose levels and the
pulse-wave augmentation index (Aindex ) , measured by a gyro sensor.

Region

Japan


Condition

Condition

Diabetes

Classification by specialty

Endocrinology and Metabolism

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

The purpose of the present study was to analyze the relationship between blood glucose levels and the pulse-wave augmentation index (Aindex), index of the reflected wave in the artery, and provide a useful non-invasive method to estimate postprandial blood glucose levels.

Basic objectives2

Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

(1)Fasting and postprandial blood glucose levels by fingertip puncture
(2)Aindex (pulse wave characteristic)

Key secondary outcomes

(1)blood pressure test
(2)pulse rate test
(3)Physical examination (Height, weight, and BMI)
(4)Fingertip puncture for blood lipids (TC, HDL cholesterol, LDL cholesterol, TG, non-HDL, Glu)
(5)blood HbA1c test by fingertip puncture


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

30 years-old <=

Age-upper limit

69 years-old >=

Gender

Male and Female

Key inclusion criteria

1)Age 30 to 69 years
2)a healthy person (Those who have no past history of chronic diseases or malignant tumors and are not under treatment for diseases or injuries.)
3)People who do not take drugs (Antihypertensives, hypnotics, antidepressants, blood, everything.)
4)Nonsmokers (> 5 yr)
5)Japanese

Key exclusion criteria

1)A person who is judged to be ineligible by the research representative.

Target sample size

220


Research contact person

Name of lead principal investigator

1st name Shiro
Middle name
Last name MINAMI

Organization

Sunmarco clinic

Division name

-

Zip code

211-0004

Address

1-825-7, Sinmaruko, Nakahara-ku, Kawasaki

TEL

044-433-3005

Email

shirom@sunmarcocl.com


Public contact

Name of contact person

1st name Hiromi
Middle name
Last name AJIMA

Organization

KYOCERA Corporation

Division name

Medical R&D Center

Zip code

220-0012

Address

3-7-1, Minatomirai, Nishi-ku, Yokohama

TEL

045-605-7090

Homepage URL


Email

hiromi.ajima.xm@kyocera.jp


Sponsor or person

Institute

KYOCERA Corporation

Institute

Department

Personal name



Funding Source

Organization

KYOCERA Corporation

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor

Macromill, Inc.
Healthcare Systems Co., Ltd.

Name of secondary funder(s)



IRB Contact (For public release)

Organization

The Ethics Committee of Healthcare Systems Co., Ltd

Address

1-14-18 Shirakane, Showa-ku, Nagoya city, Aichi, JAPAN

Tel

052-734-8885

Email

soumu@hc-sys.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2022 Year 07 Month 20 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

220

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2022 Year 06 Month 08 Day

Date of IRB

2022 Year 06 Month 29 Day

Anticipated trial start date

2022 Year 06 Month 29 Day

Last follow-up date

2022 Year 10 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

The purpose of the present study was to analyze the relationship between blood glucose levels and the pulse-wave augmentation index (Aindex), index of the reflected wave in the artery.


Management information

Registered date

2022 Year 07 Month 13 Day

Last modified on

2024 Year 03 Month 13 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055119